Who founded Natsar Pharmaceuticals?

Natsar Pharmaceuticals was founded by Venu Raman.

How much funding has Natsar Pharmaceuticals raised?

Natsar Pharmaceuticals has disclosed $4.2M raised across 1 round.

Where is Natsar Pharmaceuticals headquartered?

Natsar Pharmaceuticals is headquartered in Ellicott City, US.

Natsar Pharmaceuticals

Ellicott City, US · Delaware corporation

Find your way into Natsar Pharmaceuticals

Paths you didn't know you had: your email and LinkedIn already hold routes to the Natsar Pharmaceuticals team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Natsar Pharmaceuticals is an applied research and drug development company developing RK-33, a first-in-class small molecule inhibitor of the DDX3 RNA helicase for treating cancers such as lung, breast, prostate, sarcoma, and pancreatic tumors, as well as viral infections including SARS-CoV-2 and HIV. The company is preparing to file an IND and move RK-33 into Phase 1 clinical trials.

Biotech Longevity

Founders & leadership

Venu Raman Founder and CSOVenu Raman is a cancer biologist and professor at Johns Hopkins University who has conducted research on developmental cancer mechanisms and gene dysregulation. He founded Natsar Pharmaceuticals to develop RK-33, a small molecule inhibitor targeting the DDX3 RNA helicase for cancer and viral treatment applications.

Venu Raman Ph.DFounder & Director; Chief Scientific Officer

Reported raises · per SEC filings

Form D private placements

$4.2M disclosed across 1 round · 2026

▶$4.2MraisedMay 2026 · 15 investors · Pharmaceuticals

Rule 506(b)

Officers, directors & promoters on the filing

Venu RamanExecutive Officer, Director

Amount sold: $4.2M
Minimum investment: $1
First sale: Apr 2026
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 5

ADARx PharmaceuticalsADARx is a clinical-stage biotechnology company developing RNA-targeted therapeutics designed to control the expression of disease-driving genes. It focuses on treatments for a range of diseases with unmet medical needs.

Day One BiopharmaceuticalsDay One is a biopharmaceutical company that develops first- or best-in-class targeted medicines for children and adults with life-threatening diseases, with a focus on cancers such as pediatric brain tumors. Founded in 2018, it received its first FDA approval in 2024 for a pediatric brain tumor treatment.

Aurinia PharmaceuticalsAurinia is a biopharmaceutical company developing therapies for autoimmune diseases with significant unmet medical needs. The company's marketed product LUPKYNIS treats active lupus nephritis, and it is also developing aritinercept for broader autoimmune indications.

SamsaraSamsara Therapeutics develops small-molecule therapeutics that activate autophagy to slow the progression of age-related neurodegenerative diseases such as ALS, Parkinson's, and Charcot-Marie-Tooth disease. It runs an in-house phenotypic screening platform using patient-derived iPSCs to identify and validate autophagy activators for drug discovery.

ARS PharmaceuticalsARS Pharmaceuticals is a biopharmaceutical company developing treatments for severe allergic reactions, with a focus on patient-friendly, easy-to-use intranasal therapies. It serves patients with allergies and their caregivers.

Companies working in the same space as Natsar Pharmaceuticals.

Frequently asked questions

What does Natsar Pharmaceuticals do?: Natsar Pharmaceuticals is an applied research and drug development company developing RK-33, a first-in-class small molecule inhibitor of the DDX3 RNA helicase for treating cancers such as lung, breast, prostate, sarcoma, and pancreatic tumors, as well as viral infections including SARS-CoV-2 and HIV. The company is preparing to file an IND and move RK-33 into Phase 1 clinical trials.
Who founded Natsar Pharmaceuticals?: Natsar Pharmaceuticals was founded by Venu Raman.
How much funding has Natsar Pharmaceuticals raised?: Natsar Pharmaceuticals has disclosed $4.2M raised across 1 round.
Where is Natsar Pharmaceuticals headquartered?: Natsar Pharmaceuticals is headquartered in Ellicott City, US.